bluebird bio, Inc. (BLUE)
Chart Events
Performance Outlook
| Previous Close | 42.73 |
| Open | 43.00 |
| Bid | 42.63 x 1300 |
| Ask | 42.80 x 2900 |
| Day's Range | 42.19 - 43.20 |
| 52 Week Range | 38.95 - 99.36 |
| Volume | 1,073,332 |
| Avg. Volume | 850,613 |
| Market Cap | 2.837B |
| Beta (5Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.81 |
| Earnings Date | Feb 16, 2021 - Feb 22, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 82.33 |
- Business Wire
bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition.
- Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH MeetingGlobeNewswire
- Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual MeetingBusiness Wire
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE
NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc.
- Newsfile
SHAREHOLDER ALERT: Investigation of bluebird Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal securities laws. On November 4, 2020, the Company announced its submission to the FDA for approval of its bb1111 product will be delayed until late 2022. The price of bluebird's stock fell following the announcement. If you purchased shares of bluebird and suffered a loss on ...
